High-dose RT using SBRT or PBT has proven to be highly effective in providing excellent local tumor control of intrahepatic tumor.19,20 The Asia-Pacific primary liver cancer expert consensus also suggests considering high-dose RT for patients with unresectable HCC.21 Our prior report demonstrated that the combination of PBT with anti-PD1/PD-L1 achieved an excellent 1-year infield intrahepatic tumor control rate of 70%-90% and effectively obtained an ORR of 43.8%-61.5%. The gene discussed is CD274; the disease is hepatocellular carcinoma.